Guardant Health (GH) Stock
Blood test leader for cancer detection and treatment. Here's the price, business snapshot, and what's worth knowing about Guardant Health in August 2026.
Guardant Health, Inc. (GH) develops blood-based (liquid biopsy) tests and analytics for cancer detection, treatment selection and disease monitoring. Its products — including tumour profiling assays used for therapy decisions and tests aimed at early detection — leverage genomic sequencing and clinical data to address unmet needs in precision oncology. The company competes on technology, clinical validation and partnerships with biopharma and health systems, while seeking broader reimbursement and adoption. Guardant’s market cap is around $8.42 billion; investors should weigh potential growth from expanding test use against execution, regulatory, reimbursement and competitive risks. Financial performance has varied as the company invests in R&D and commercial expansion. This summary is educational only and not investment advice; suitability depends on an investor’s objectives, risk tolerance and timeframe, and past performance is not a reliable guide to future results.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Guardant Health's stock, anticipating significant price growth potential.
Financial Health
Guardant Health is producing strong revenue and cash flow, supported by a healthy profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Growth in Oncology Testing
Rising use of targeted therapies can increase demand for genomic tests, though adoption depends on guidelines and reimbursement which can take time.
Technology and Data
Combining sequencing with clinical datasets may create differentiation, yet technological competition and validation needs remain important considerations.
Market and Reimbursement
Expansion into new markets and payer coverage would support revenue, but regulatory and reimbursement outcomes introduce meaningful uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
